Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: MannKind Corporation

Market Cap 1.2B 1.03B 948M 893M 1.68B 113B 1.69B 11.24B 4.38B 55.38B 4.49B 4.39B 192B P/E 2026 *
-123x
P/E 2027 * 27.2x
Enterprise Value 1.2B 1.03B 948M 893M 1.68B 113B 1.69B 11.24B 4.38B 55.38B 4.49B 4.39B 192B EV / Sales 2026 *
2.59x
EV / Sales 2027 * 2.29x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day+3.23%
1 week+10.06%
Current month+5.97%
1 month+33.61%
3 months+46.34%
6 months-33.08%
Current year-29.54%
1 week 3.55
Extreme 3.55
4.06
1 month 2.93
Extreme 2.93
4.06
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 2017-05-24
Director of Finance/CFO 50 2024-04-21
Chief Tech/Sci/R&D Officer - 2025-09-28
Director TitleAgeSince
Director/Board Member 82 2003-09-30
Director/Board Member 82 2003-11-30
Chairman 69 2020-12-08
Date Insider Type Main position Quantity % Market Cap.
05-19Other

Director

82,781 0.0268%
05-19Free

Director

82,781 0.0268%
05-19Other

Director

82,781 0.0268%
Change 5-day change 1-year change 3-year change Capi.($)
+3.23%+10.06%+6.53%-0.62% 1.2B
+3.23%+2.25%+65.02%+116.66% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.84%+7.86%-11.48%-15.48% 22.63B
+3.00%+6.76%-2.18%+385.38% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.87%+13.67%-38.00% 14.83B
+1.21%+0.42%+27.68%+178.78% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.21%+6.22%+79.06%+103.95% 11.56B
Average +1.40%+1.00%+24.75%+81.15% 21.09B
Weighted average by Cap. +1.66%+0.23%+33.19%+90.77%

Financials

2026 *2027 *
Net sales 462M 398M 366M 345M 648M 43.58B 653M 4.34B 1.69B 21.39B 1.73B 1.7B 73.99B 521M 449M 413M 389M 731M 49.17B 737M 4.9B 1.91B 24.13B 1.96B 1.91B 83.48B
Net income -501K -433K -398K -374K -703K -47.32M -709K -4.71M -1.83M -23.22M -1.88M -1.84M -80.34M 56.85M 49.04M 45.09M 42.44M 79.75M 5.37B 80.42M 534M 208M 2.63B 213M 209M 9.11B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
26-06-17 3.995 $ +3.23% 1,248,454
26-06-16 3.870 $ -3.25% 3,164,062
26-06-15 4.000 $ +9.29% 5,605,230
26-06-12 3.660 $ -2.40% 3,844,283
26-06-11 3.750 $ +3.31% 4,071,347
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.870USD
Average target price
7.594USD
Spread / Average Target
+96.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!